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 Abstract  While there are many blood and/or tissue biomarkers as well as algorithms 
clinically used to assess hepatic ﬁ brosis, a good biomarker and therapeutic target of 
hepatic ﬁ brogenesis, which reﬂ ects preﬁ brotic changes, has not been established. 
The most ﬁ brogenic cytokine, transforming growth factor (TGF)-β, is produced as 
a latent complex, in which TGF-β is trapped by its propeptide. On the surface of 
activated hepatic stellate cells, plasma kallikrein activates TGF-β by cleaving 
latency-associated protein (LAP) between the R 58 and L 59 residues, releasing active 
TGF-β from the complex. We made speciﬁ c antibodies that recognize neo-C-terminal 
(R 58 ) and N-terminal (L 59 ) ends of LAP degradation products (LAP- DPs) and found 
that LAP-DPs may serve as a novel surrogate marker of TGF-β activation—namely, 
generation of active TGF-β—and is thus a therapeutic marker for TGF-β-mediated 
liver ﬁ brogenesis in patients and can also be used to monitor effects of anti-ﬁ brogenic 
factors or compounds for discovery of a novel anti-ﬁ brosis drug. 
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 Abbreviations 
 ECM  Extracellular matrix 
 HSCs  Hepatic stellate cells 
 αSMA  α smooth muscle actin 
 TGF-β1  Transforming growth factor-β1 
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 LAP  Latency associated protein 
 SLC  Small latent complex 
 LTBP  Latent TGF-β binding protein 
 LLC  Large latent complex 
 PLN  Plasmin 
 PLK  Plasma kallikrein 
 LAP-DP  LAP degradation products 
 LAP β1  TGF-β1 LAP 
 BDL  Bile duct ligation 
 HBV  Hepatitis B virus 
 HCV  Hepatitis C virus 
 NASH  Non-alcoholic steatohepatitis 
 Introduction of Liver Fibrogenesis 
 Hepatic ﬁ brosis is the excessive accumulation of extracellular matrices (ECM; 
mainly collagen) in the perisinusoidal space (or space of Disse) in the liver, and an 
important pathological step developing from chronic hepatitis to liver cirrhosis irre-
spective of etiologies [ 1 ], whereas hepatic ﬁ brogenesis means ﬁ brosis progression 
or an ongoing reaction producing excessive ECM, sometimes nonsymptomatic, in 
the liver [ 2 ]. While there are many blood and/or tissue biomarkers as well as 
algorithms clinically used to assess hepatic ﬁ brosis [ 3 – 7 ], the gold standard is still 
scoring of stained collagen ﬁ bers in the biopsy sample [ 3 ]. However, biopsy is 
invasive and risky. Imaging techniques including ultrasound elastography have been 
developed [ 3 ]. In contrast, a good biomarker and therapeutic target of hepatic ﬁ bro-
genesis, which reﬂ ects preﬁ brotic changes, has not been established [ 2 , 3 ]. Therefore, 
development of a noninvasive biomarker for hepatic ﬁ brogenesis, which will lead 
not only to establishment of a novel diagnosis useful to prevent liver ﬁ brosis/
cirrhosis, but also to acceleration of drug discovery and development against liver 
ﬁ brosis, is in high demand [ 3 ]. 
 Activation of Hepatic Stellate Cells 
 Hepatic stellate cells (HSCs) play a central role in the pathogenesis of hepatic ﬁ bro-
sis by virtue of their ability to undergo a process termed “activation” [ 1 , 2 ]. During 
this process, HSCs transform into myoﬁ broblast-like cells accompanying several 
key phenotypic changes, which collectively increase extracellular matrix accumula-
tion [ 1 – 3 ]. These include (1) cellular proliferation caused by upregulation of mito-
genic cytokines and their receptors; (2) morphologic changes with loss of stored 
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vitamin A droplets; (3) contractility caused by increased α smooth muscle actin 
(αSMA), which may constrict sinusoidal blood ﬂ ow; and (4) ﬁ brogenesis mainly 
caused by increased synthesis and release of collagen. 
 TGF-β and Its Activation Reaction 
 Among many cytokines and growth factors related to ﬁ brogenesis, the most potent—
and therefore the most “ﬁ brogenic”—cytokine is the 25 kD homodimeric cytokine, 
transforming growth factor (TGF)-β [ 8 ]. The TGF-β family is composed of three 
subtypes (TGF-β1, TGF-β2, and TGF-β3), with biological properties that are nearly 
identical [ 8 ]. TGF-β is produced as an inactive latent complex, in which active 
TGF-β is trapped by its propeptide, latency-associated protein (LAP), and to exert 
its biological activities, it must be released from the complex [ 9 ]. This reaction is 

























 Fig. 1  TGF-β activation and signaling pathway. TGF-β is produced as a latent complex (LLC) 
composed of active TGF-β trapped by its propeptide LAP (SLC) and a matrix protein LTBP. Upon 
cleavage of LAP by proteases such as PLK, active TGF-β is released from the complex (this reac-
tion is called TGF-β activation) and exerts ﬁ brogenic activity (stimulation of collagen synthesis) 
via binding to its receptors and Smad signaling 
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precursor protein consisting of a signal peptide of 29 amino acids, an N-terminal 
LAP, and a C-terminal region that becomes the active TGF-β1 molecule, and each 
region is dimerized through S–S bonds. After processing by cleavage at R 278 –A 279 
by a furin-like protease, the LAP still non-covalently captures the active TGF-β1, 
forming small latent complex (SLC) and preventing active TGF-β1 from binding its 
cognate receptors [ 9 ]. The active TGF-β1 and the LAP homodimers are 25 kD and 
75 kD, respectively. SLC is S–S bonded to another gene product, the latent TGF-β 
binding protein (LTBP), via C 33 residues, forming the large latent complex (LLC). 
This complex can be sequestered in the ECM (Fig.  1 ) [ 10 ] because LTBP is a mem-
ber of an ECM protein family, ﬁ brillin [ 11 ].
 Activation of latent TGF-β is performed through different mechanisms depend-
ing on the tissue and cell types and experimental conditions, and several molecules 
are known to activate TGF-β1 in animal models [ 12 – 21 ]. These include integrins 
[ 12 – 15 ], thrombospondin [ 16 ], and proteases, such as matrix metalloproteinases 
and serine proteases [ 17 – 21 ]. The integrin αvβ6 binds to and activates latent TGF-β 
and plays a role in regulating pulmonary inﬂ ammation and ﬁ brosis as well as biliary 
ﬁ brosis [ 12 – 15 ]. Thrombospondin 1 is another major activator of latent TGF-β, 
especially in the lung and pancreas, by binding to a deﬁ ned site within LAP and 
inducing a conformational change in the latent complex [ 16 ]. In the normal liver, 
TGF-β is produced and secreted from sinusoidal endothelial cells and Kupffer cells 
(KCs, resident macrophages in the liver) at low levels. Elevated production of 
TGF-β was seen ﬁ rst in all cell types and then mainly in hepatocytes and HSCs after 
partial hepatectomy, whereas elevated production of TGF-β was seen solely in 
HSCs after inﬂ ammation and ﬁ brosis [ 22 ]. TGF-β secreted from HPCs is entirely in 
the latent form, whereas TGF-β secreted from HSCs is 50–90 % in the active form 
[ 22 ]. Thus, HSCs are recognized as the major source of active TGF-β, namely the 
site of TGF-β activation, particularly in the damaged liver [ 22 , 23 ]. 
 We have addressed a potential proteolytic mechanism for latent TGF-β activation 
in HSCs by surface plasmin (PLN) and plasma kallikrein (PLK) during the forma-
tion of hepatic ﬁ brosis [ 20 , 21 ]. PLN releases latent TGF-β from the extracellular 
matrix and activates it by cleaving LAP from latent TGF-β molecules on the HSC 
surface [ 9 , 20 ]. Lyons et al. ﬁ rst reported that PLN digests LAP and activates TGF- 
β1 in vitro [ 24 ]. Using a protease inhibitor, camostat mesilate, we demonstrated that 
PLN and PLK are involved in the TGF-β1 activation associated with liver ﬁ brosis 
and impaired liver regeneration in animal models [ 20 , 21 ]. However, it remained to 
be elucidated whether PLN- and/or PLK-dependent TGF-β1 activation also occurs 
during the pathogenesis of liver ﬁ brosis in patients, as there was no good biomarker 
reﬂ ecting protease-dependent TGF-β1 activation reaction. To answer this question, 
we determined cleavage site within LAP and made speciﬁ c antibodies that recog-
nize LAP degradation products (LAP-DPs) bearing a neo-amino or carboxyl termi-
nus [ 25 ]. 
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 TGF-β LAP-DP Serves as a Surrogate Marker for Its 
Activation Reaction 
 To identify the cleavage sites in LAP during latent TGF-β1 activation by PLN and 
PLK, recombinant human LAP β1 was digested with these proteases, the resultant 
fragments were separated by SDS-polyacrylamide gel electrophoresis (PAGE), and 
the N-terminal sequence of each LAP-DP was determined using a pulsed liquid 
protein sequencer Precise 494cLC, which revealed that PLN and PLK primarily 
cleave LAP β1 between the K 56 and L 57 residues, and the R 58 and L 59 residues, 
respectively, during proteolytic activation of latent TGF-β1 (Fig.  2 ) [ 25 ].













































 Fig. 2  Cleavage of K 56 LRL 59 within LAP activates TGF-β. PLN and PLK cleave LAP between 
K 56 –L 59 and R 58 –L 59 residues, respectively, causing release of active TGF-β1 from the latent com-
plex. The amino acid sequences around the PLN and PLK cleavage sites are illustrated. Antibodies 
that speciﬁ cally recognize the cutting edges of LAP-DPs were produced. The  dark blue “Y” 
labeled R58 represents antibodies recognizing the C-terminal or N-terminal side LAP-DPs, 
whereas the  red “Y” labeled L59 represents antibodies recognizing the N-terminal or C-terminal 
side LAP-DPs. A comparison of amino acid sequences from the N-terminus until the PLK cleav-
age site among three isoforms of TGF-β is presented at the bottom 
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 To detect PLK-produced LAP-DPs, we made two monoclonal antibodies. One is 
the R58 antibody detecting N-terminal side LAP-DPs terminating on the R 58 residue 
(R 58 LAP-DPs), and another is the L59 antibody detecting C-terminal side LAP- 
DPs starting from the L 59 residue (L 59 LAP-DPs). We established techniques to 
detect each LAP-DP using these antibodies [ 25 ]. The R 58 LAP-DPs remaining in 
tissues or cell surfaces through S–S bonded LTBP can be detected mostly in αSMA- 
positive activated stellate cells in liver tissues from both ﬁ brotic animals and patients 
by immunostaining with the R58 antibody, whereas the L 59 LAP-DPs were not 
detectable by immunostaining with the L59 antibody [ 25 ]. Figure  3 shows the 
results obtained from bile duct ligation (BDL) mice. These mice often exhibited 
granulomatous lesions ( panel a ), in which ﬁ broblastic cells inﬁ ltrated and started 
ECM production ( panel b ). Importantly, the R 58 LAP-DPs were detected in granu-
lomatous lesions prior to Sirius red positivity, namely before collagen accumulation 
(arrowheads in  panel c ). In contrast, L59 antibody failed to stain the L 59 LAP-DPs, 
although various antigen unmasking procedures were treated ( panel d ). We found 
that the L 59 LAP-DPs were released into the blood and could be measured by an 
ELISA using the L59 antibody (Hara et al., unpublished data). In panels  e–h , non-
parenchymal regions were recognized by antibody R58 (arrowheads in  panel e ), 
and mostly overlapped with αSMA-positive HSCs (arrowheads in  panel f ), but not 
with CD31-positive liver sinusoidal endothelial cells ( panel g ) nor with CD68- 
positive KCs (hepatic macrophages) ( panel h ). We further found that the R58 
antibody detected TGF-β1/3 LAP-DPs but not TGF-β2 LAP-DPs because of the 
similarity and difference of the R58 side sequence, respectively (Fig.  2 ). Finally, we 
succeeded in detecting R 58 LAP-DPs in patients with chronic hepatitis B and C virus 
 Fig. 3  Emergence of TGF-β LAP-DPs in activated HSCs within pre-ﬁ brotic areas in BDL mod-
els. Liver sections from BDL-operated mice were stained by HE ( a ) and Sirius red ( b ), and immu-
nostained with R58 ( c ) and L59 ( d ) antibodies (scale bar = 50 μm), and were immunostained with 
R58 ( e ), anti-αSMA ( f ), anti-CD31 ( g ), and anti-CD68 ( h ) antibodies (scale bar = 25 μm). More 
detailed results are provided elsewhere [ 25 ] 
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(HBV and HCV, respectively) infection categorized as A1F2 and A2F2, as well as 
in patients with non-viral hepatitis, such as autoimmune hepatitis and non-alcoholic 
steatohepatitis (NASH) [ 25 ]. A speciﬁ c cell shape called a “crown-like structure” 
(CLS) has been referred to as a biomarker for NASH in both an animal model and 
patients [ 26 ]. Recently, we found that R 58 LAP-DPs positivity well matched the 
emergence of CLS [ 27 ].
 These data suggest the occurrence of a PLK-dependent TGF-β activation reac-
tion in patients and indicate that the LAP-DP may be useful as a surrogate marker 
reﬂ ecting PLK-dependent TGF-β1/3 activation and subsequent ﬁ brogenesis in the 
ﬁ brotic liver both in animal models and in patients. 
 Conclusion and Future Subjects 
 The most ﬁ brogenic cytokine, TGF-β, is produced as a latent complex, in which 
TGF-β is trapped by its propeptide, LAP. On the surface of activated HSCs, PLK 
activates TGF-β by cleaving LAP between the R 58 and L 59 residues, releasing active 
TGF-β from the complex. We made speciﬁ c antibodies that recognize the neo-C- 
terminal (R 58 ) and N-terminal (L 59 ) ends of the LAP-DP, and found that the LAP-DP 
may serve as a novel surrogate marker of TGF-β activation—namely, generation of 
active TGF-β—and is thereby a therapeutic marker for TGF-β-mediated liver ﬁ bro-
genesis in patients [ 25 ]. 
 Utilizing LAP-DP antibodies, we are developing techniques to visualize the 
ﬁ brogenic area by positron emission tomography (PET), planning to eliminate 
 activated HSCs with pertussis toxin, and undertaking the challenge to solve the 
 co- crystal structure of LAP and a LAP-DP targeting inhibitor, which binds to the 
LAP cleavage site, thereby inhibiting TGF-β activation and liver ﬁ brosis in HBV-
infected chimeric mice (Hara et al., unpublished data). The effectiveness of an 
inhibitor against the TGF-β activation reaction has been reported in the integrin-
mediated activation of TGF-β [ 3 ,  15 ,  28 ]. LAP-DP is also used to monitor the effects 
of anti- ﬁ brogenic factors or compounds for discovery of a novel anti-ﬁ brosis drug. 
For example, we recently found that HCV NS3 protease mimics TGF-β2 and 
enhances liver ﬁ brosis via binding to and activation of the TGF-β type I receptor, 
and that an anti-NS3 antibody raised against the predicted binding sites attenuates 
liver ﬁ brosis in HCV-infected chimeric mice [ 29 ]. In this study, R58 LAP-DP stain-
ing nicely showed the anti-ﬁ brogenic potentials of the anti-NS3 antibody. 
 The technique developed accelerates drug discovery targeting TGF-β-dependent 
ﬁ brogenesis in patients suffering from chronic hepatitis. 
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